FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2172108666> ?p ?o ?g. }

• W2172108666 endingPage "802.e3" @default.
• W2172108666 startingPage "788" @default.
• W2172108666 abstract "Tocilizumab (TCZ), a humanized anti–interleukin-6 receptor monoclonal antibody, represents a new treatment strategy for patients with rheumatoid arthritis (RA) and is currently approved in the United States for RA patients who have failed to improve with at least one anti–tumor necrosis factor therapy. The goal of this study was to summarize the efficacy and safety profile of TCZ. A systematic literature review was conducted to identify English-language articles within PubMed and the Cochrane Library from January 1989 to August 2011 reporting results from Phase III TCZ double-blind, randomized controlled trials (RCTs), noncontrolled clinical trials, and open-label extensions with a duration ≥6 months. Study outcomes had to include at least one of the following: American College of Rheumatology (ACR) 20, 50, or 70 response rates; tender/swollen joint count; Health Assessment Questionnaire–Disability Index; radiographic outcomes and drug persistence. Phase II RCTs were included only if they contained relevant information not available in Phase III RCTs. Relevant studies were selected to evaluate TCZ's pharmacokinetics and pharmacodynamics. Ten published clinical trials (7 Phase III, 3 Phase II) for TCZ were retrieved (7833 articles initially identified) from PubMed and 31 from the Cochrane library. Compared with methotrexate (MTX) monotherapy, TCZ 8 mg/kg IV monotherapy had higher rates of ACR20 (P < 0.001), ACR50 (P = 0.002), and ACR70 (P < 0.001) scores at week 24. TCZ 8 mg/kg IV plus oral MTX had a higher ACR20 response rate than oral MTX plus placebo in patients with RA who failed to respond to MTX or anti–tumor necrosis factor therapy (P < 0.001). Patients receiving TCZ 8 mg/kg had less radiographic progression on the Genant-modified Sharp score (85% had no progression) than the control group (67% had no progression) (P < 0.001). The rate of serious infections was 4.7 events/100 patient-years of exposure in the TCZ groups. A greater frequency of neutropenia, thrombocytopenia, hyperlipidemia, and transaminitis was observed with TCZ compared with placebo. The short-term efficacy and safety profile of TCZ is promising. Additional long-term safety data are needed to better characterize the risk–benefit profile of this agent." @default.
• W2172108666 created "2016-06-24" @default.
• W2172108666 creator A5000754711 @default.
• W2172108666 creator A5046999547 @default.
• W2172108666 creator A5057080481 @default.
• W2172108666 date "2012-04-01" @default.
• W2172108666 modified "2023-09-27" @default.
• W2172108666 title "Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor" @default.
• W2172108666 cites W1856703017 @default.
• W2172108666 cites W1969791558 @default.
• W2172108666 cites W1974457163 @default.
• W2172108666 cites W1983224547 @default.
• W2172108666 cites W1985953874 @default.
• W2172108666 cites W1987192197 @default.
• W2172108666 cites W1996389186 @default.
• W2172108666 cites W1996548067 @default.
• W2172108666 cites W1997568521 @default.
• W2172108666 cites W2007872832 @default.
• W2172108666 cites W2017223857 @default.
• W2172108666 cites W2022713850 @default.
• W2172108666 cites W2033299724 @default.
• W2172108666 cites W2037010889 @default.
• W2172108666 cites W2054059257 @default.
• W2172108666 cites W2054438120 @default.
• W2172108666 cites W2054789510 @default.
• W2172108666 cites W2058627561 @default.
• W2172108666 cites W2062697678 @default.
• W2172108666 cites W2063407488 @default.
• W2172108666 cites W2063485775 @default.
• W2172108666 cites W2067797433 @default.
• W2172108666 cites W2069070533 @default.
• W2172108666 cites W2069473482 @default.
• W2172108666 cites W2074438676 @default.
• W2172108666 cites W2078839890 @default.
• W2172108666 cites W2079590652 @default.
• W2172108666 cites W2084758773 @default.
• W2172108666 cites W2096862304 @default.
• W2172108666 cites W2103775523 @default.
• W2172108666 cites W2110995918 @default.
• W2172108666 cites W2114308202 @default.
• W2172108666 cites W2116843833 @default.
• W2172108666 cites W2120852203 @default.
• W2172108666 cites W2125212735 @default.
• W2172108666 cites W2134069361 @default.
• W2172108666 cites W2137393768 @default.
• W2172108666 cites W2139339400 @default.
• W2172108666 cites W2141171232 @default.
• W2172108666 cites W2143875454 @default.
• W2172108666 cites W2145573746 @default.
• W2172108666 cites W2150952126 @default.
• W2172108666 cites W2156996668 @default.
• W2172108666 cites W2159106700 @default.
• W2172108666 cites W2159705610 @default.
• W2172108666 cites W2164481110 @default.
• W2172108666 cites W2166396307 @default.
• W2172108666 cites W2166732840 @default.
• W2172108666 cites W2170549897 @default.
• W2172108666 cites W2172201422 @default.
• W2172108666 cites W2336588424 @default.
• W2172108666 doi "https://doi.org/10.1016/j.clinthera.2012.02.014" @default.
• W2172108666 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3805022" @default.
• W2172108666 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22444783" @default.
• W2172108666 hasPublicationYear "2012" @default.
• W2172108666 type Work @default.
• W2172108666 sameAs 2172108666 @default.
• W2172108666 citedByCount "124" @default.
• W2172108666 countsByYear W21721086662012 @default.
• W2172108666 countsByYear W21721086662013 @default.
• W2172108666 countsByYear W21721086662014 @default.
• W2172108666 countsByYear W21721086662015 @default.
• W2172108666 countsByYear W21721086662016 @default.
• W2172108666 countsByYear W21721086662017 @default.
• W2172108666 countsByYear W21721086662018 @default.
• W2172108666 countsByYear W21721086662019 @default.
• W2172108666 countsByYear W21721086662020 @default.
• W2172108666 countsByYear W21721086662021 @default.
• W2172108666 countsByYear W21721086662022 @default.
• W2172108666 countsByYear W21721086662023 @default.
• W2172108666 crossrefType "journal-article" @default.
• W2172108666 hasAuthorship W2172108666A5000754711 @default.
• W2172108666 hasAuthorship W2172108666A5046999547 @default.
• W2172108666 hasAuthorship W2172108666A5057080481 @default.
• W2172108666 hasBestOaLocation W21721086662 @default.
• W2172108666 hasConcept C111113717 @default.
• W2172108666 hasConcept C112705442 @default.
• W2172108666 hasConcept C126322002 @default.
• W2172108666 hasConcept C142724271 @default.
• W2172108666 hasConcept C168563851 @default.
• W2172108666 hasConcept C197934379 @default.
• W2172108666 hasConcept C198451711 @default.
• W2172108666 hasConcept C204787440 @default.
• W2172108666 hasConcept C27081682 @default.
• W2172108666 hasConcept C2776478404 @default.
• W2172108666 hasConcept C2777178219 @default.
• W2172108666 hasConcept C2777575956 @default.
• W2172108666 hasConcept C2781059491 @default.
• W2172108666 hasConcept C535046627 @default.
• W2172108666 hasConcept C71924100 @default.

• next